Voss, M. H., Gordon, M. S., Mita, M., Rini, B., Makker, V., Macarulla, T., . . . Burris, H. A. (2020). Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. Br J Cancer.
Citação norma ChicagoVoss, Martin H., et al. "Phase 1 Study of MTORC1/2 Inhibitor Sapanisertib (TAK-228) in Advanced Solid Tumours, With an Expansion Phase in Renal, Endometrial or Bladder Cancer." Br J Cancer 2020.
Citação norma MLAVoss, Martin H., et al. "Phase 1 Study of MTORC1/2 Inhibitor Sapanisertib (TAK-228) in Advanced Solid Tumours, With an Expansion Phase in Renal, Endometrial or Bladder Cancer." Br J Cancer 2020.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.